Tradestie Institutional Equity Comparison Engine
MRNA vs BEAM โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
MRNA Overall Edge
MRNA Captures Institutional Edge (4โ0 Pillars ยท 7โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Moderna, Inc. Common Stock (MRNA) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, MRNA trades at 23.0x Forward P/E with -80.8% operating margin (+29.2% YoY revenue) versus BEAM at N/M Forward P/E and -267.7% operating margin (-96.8% YoY). In options structure, MRNA sits in CONSOLIDATION (52nd %ile IV; Dealer Gamma Walls on Pro) against BEAM sits in BREAKDOWN (34th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
MRNA
MRNA 23.0x vs BEAM N/M Fwd P/E
Growth & Margin Winner
MRNA
Op Margin -80.8% vs -267.7% ยท YoY +29.2% vs -96.8%
Momentum & Technical Winner
MRNA
1Y +706.5% vs -0.4% ยท 52W Pos 67% vs 4%
Options & Structure Winner
MRNA
CONSOLIDATION (52nd %ile IV) vs BREAKDOWN (34th %ile IV)
MRNA
NASDAQ
Moderna, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$195.00
-2.17% 1D
Market Cap
$80.7B
1M Return
-3.77%
1Y Return
+706.45%
Forward P/E
23.0x
Unified AI Score
40.3 / 100
SELL
Tech 18.0
Fund 42.0
Flow 67.0
Mom 46.0
BEAM
NASDAQ
Beam Therapeutics Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$20.90
-0.19% 1D
Market Cap
$2.2B
1M Return
-14.9%
1Y Return
-0.38%
Forward P/E
N/M
Unified AI Score
60.3 / 100
BUY
Tech 70.0
Fund 66.0
Flow 67.0
Mom 60.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
MRNA +706.45%
BEAM -0.38%
Spread: +706.83 pp (MRNA Lead)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | MRNA Revenue | BEAM Revenue | MRNA Op. Margin | BEAM Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $140M | N/A | -306.0% | N/A | MRNA |
| FY2019 | $60M | $0M | -906.8% | -417522.2% | MRNA |
| FY2020 | $800M | $0M | -95.0% | -553166.7% | MRNA |
| FY2021 | $18.5B | $50M | 72.0% | -757.0% | MRNA |
| FY2022 | $19.3B | $60M | 48.9% | -555.6% | MRNA |
| FY2023 | $6.85B | $380M | -61.9% | -46.7% | BEAM |
| FY2024 | $3.24B | $60M | -121.9% | -654.3% | MRNA |
| FY2025 | $1.94B | $140M | -158.1% | -274.6% | MRNA |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | MRNA | BEAM | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $80.7B | $2.2B | Larger Scale | MRNA |
| Trailing P/E Ratio Valuation | 23.0x | N/M | Lower Multiple | MRNA |
| Forward P/E Ratio Valuation | 23.0x | N/M | Lower Multiple | MRNA |
| Revenue Growth (YoY) Growth | +29.2% | -96.8% | Higher Growth | MRNA |
| Operating Margin (TTM) Profitability | -80.8% | -267.7% | Higher Margin | MRNA |
| Net Profit Margin Profitability | -110.5% | -73.9% | Higher Margin | BEAM |
| Return on Equity (ROE) Capital Efficiency | -34.5% | -11.3% | Higher ROE | BEAM |
| 52-Week Range Position Momentum | 67% ($22โ$281) | 4% ($20โ$38) | Stronger Trend | MRNA |
| Beta / 30D Volatility Risk Regime | 2.23ฮฒ ยท 78% Vol | 2.09ฮฒ ยท 86% Vol | Lower Realized Risk | MRNA |
| Unified Institutional Score Composite Signal | 40.3 / 100 (SELL) | 60.3 / 100 (BUY) | Higher Composite | BEAM |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full MRNA vs BEAM Buy Guide
MRNA
CONSOLIDATION
22d in phase ยท OBV DISTRIBUTION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
52nd %ile
IV Regime
Balanced (25thโ60th %ile)
BEAM
BREAKDOWN
107d in phase ยท OBV DISTRIBUTION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
34th %ile
IV Regime
Balanced (25thโ60th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither MRNA nor BEAM registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.